RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
1.000
0.00 (0.00%)
At close: Jun 4, 2026, 4:00 PM EDT
0.9860
-0.0140 (-1.40%)
After-hours: Jun 4, 2026, 7:29 PM EDT
RedHill Biopharma Employees
RedHill Biopharma had 13 employees as of December 31, 2025. The number of employees decreased by 22 or -62.86% compared to the previous year.
Employees
13
Change (1Y)
-22
Growth (1Y)
-62.86%
Revenue / Employee
$22,000
Profits / Employee
-$33,000
Market Cap
5.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | -22 | -62.86% |
| Dec 31, 2024 | 35 | -18 | -33.96% |
| Dec 31, 2023 | 53 | -60 | -53.10% |
| Dec 31, 2022 | 113 | -88 | -43.78% |
| Dec 31, 2021 | 201 | 19 | 10.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Universe Pharmaceuticals INC | 216 |
| Biofrontera | 94 |
| China SXT Pharmaceuticals | 75 |
| Sunshine Biopharma | 50 |
| cbdMD | 42 |
| InMed Pharmaceuticals | 13 |
| Gelteq | 8 |
| Sonoma Pharmaceuticals | 8 |
RDHL News
- 2 days ago - RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms - PRNewsWire
- 9 days ago - Bessor Announces Entering Option for the Redhill Property - GlobeNewsWire
- 18 days ago - RedHill Biopharma Slides: Corporate presentation - Filings
- 5 weeks ago - RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease - TheFly
- 5 weeks ago - RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease - PRNewsWire
- 5 weeks ago - RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights - PRNewsWire
- 6 weeks ago - RedHill Biopharma announces presentation of preclinical data on opaganib at AACR - TheFly
- 6 weeks ago - RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 - PRNewsWire